<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173301</url>
  </required_header>
  <id_info>
    <org_study_id>XP-H-093</org_study_id>
    <nct_id>NCT02173301</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XenoPort, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XenoPort, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study are:

        1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of
           moderate-to-severe chronic plaque-type psoriasis.

        2. To evaluate the safety and tolerability of XP23829 in subjects with psoriasis.

        3. To evaluate the pharmacodynamics (PD) of XP23829 through immunological analysis of
           peripheral blood samples.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• The percent change in PASI (Psoriasis Area and Severity Index) score from Baseline</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Proportion of subjects who achieve a reduction of 75% or greater from Baseline in PASI (PASI-75)</measure>
    <time_frame>Weeks 2, 4, 8, 12, 14 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion of subjects who achieve a sPGA (static Physician's Global Assessment) score of clear or almost clear</measure>
    <time_frame>Weeks 2, 4, 8, 12, 14 and 16</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>XP23829 400 mg QD (once daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP23829 800 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP23829 400 mg BID (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP23829 400 mg QD</intervention_name>
    <description>XP23829 400 mg QD</description>
    <arm_group_label>XP23829 400 mg QD (once daily)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP 23829 800 mg QD</intervention_name>
    <description>XP23829 800 mg QD</description>
    <arm_group_label>XP23829 800 mg QD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP23829 400 mg BID</intervention_name>
    <description>XP23829 400 mg BID</description>
    <arm_group_label>XP23829 400 mg BID (twice daily)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects, age ≥ 18.

          2. Stable, moderate-to-severe plaque-type psoriasis diagnosed for at least 6 months prior
             to randomization (no morphology changes or significant flares of disease activity in
             the last 6 months in the opinion of the investigator).

          3. Severity of disease meeting all of the following three criteria prior to
             randomization:

               1. Psoriasis Area and Severity Index (PASI) score of 12 or greater

               2. Total Body Surface Area (BSA) affected by plaque psoriasis of 10% or greater

               3. Static Physician's Global Assessment (sPGA) score of 3 or greater

          4. Must be a candidate for phototherapy and/or systemic therapy for psoriasis.

        Exclusion Criteria:

          1. Subjects with current inverse, erythrodermic, predominantly guttate, or pustular
             psoriasis.

          2. Subjects with current drug-induced or drug-exacerbated psoriasis.

          3. Subjects with moderate-to-severe psoriatic arthritis of any type; and subjects with
             mild psoriatic arthritis, who require systemic disease-modifying therapy.

          4. Subjects with unstable or significant illness, including the presence of laboratory
             abnormalities at screening that in the opinion of the investigator would place the
             subject at unacceptable risk if he/she were to participate in the study.

          5. Any skin condition (e.g. eczema) which confounds the ability to interpret data from
             the study.

          6. Treatment with a topical anti-psoriatic therapy within 14 days prior to randomization
             (including topical steroids, topical vitamin A or D analog preparations, tacrolimus,
             pimecrolimus, or anthralin).

          7. Phototherapy or prolonged sun exposure or use of ultraviolet (UV) light sources within
             28 days of randomization.

          8. Use of investigational or approved biologic treatments that are known to affect
             psoriasis, such as adalimumab, etanercept, golimumab or infliximab within 12 weeks of
             randomization and ustekinumab within 24 weeks of randomization.

          9. Use of systemic medications (non-biologics) that are known to affect psoriasis
             (including but not limited to oral corticosteroids, cyclosporine, methotrexate,
             lithium, and beta-adrenergic blockers) within 4 weeks of randomization, or 5
             half-lives, whichever is longer.

         10. Prior treatment with Dimethyl Fumarate (Fumaderm® or Tecfidera®) or any other Fumaric
             Acid Ester (FAE) containing products.

         11. Have failed (due to inadequate response) more than 3 approved systemic agents for the
             treatment of psoriasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Lissin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>XenoPort, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

